Allogeneic stem cell transplantation in children with acute lymphoblastic leukemia after isolated central nervous system relapse: our experiences and review of the literature.
The prognosis of patients with acute lymphoblastic leukemia (ALL) and central nervous system (CNS) relapse has historically been very poor. Although chemo-radiotherapy has improved outcomes, some patients still have a poor prognosis after CNS relapse. Therefore, allogeneic hematopoietic stem cell transplantation (allo-SCT) has recently become an option for treatment of CNS leukemia; however, information, particularly on the long-term outcome of transplant recipients, is limited. We performed allo-SCT in eight pediatric patients with ALL (n=7) or T-cell type non-Hodgkin's lymphoma (n=1), who had isolated CNS relapse. All patients survived for a median of 70.5 (range, 13-153) months after SCT. Sequelae developed late in some patients: mental retardation (IQ=47) in one patient, severe alopecia in two patients, limited chronic graft-versus-host-disease in three patients, and amenorrhea and/or hypothyroidism in three patients. Except for a pre-school child with post transplant CNS relapse, six out of seven patients show normal school/social performance. Our results clearly indicate a high cure rate of isolated CNS relapse by allo-SCT in pediatric lymphoid malignancies; however, there needs to be further studies to determine which are the appropriate candidates for transplantation and what is the best transplant regimen to achieve high cure rate and maintain good quality of life.
Yoshihara
T
T
Department of Pediatrics, Matsushita Memorial Hospital, Osaka, Japan. yoshihara.takao@jp.panasonic.com
Morimoto
A
A
Kuroda
H
H
Imamura
T
T
Ishida
H
H
Tsunamoto
K
K
Naya
M
M
Hibi
S
S
Todo
S
S
Imashuku
S
S
D000293:Adolescent; D000568:Amenorrhea / Q000209:etiology / Q000401:mortality; D016543:Central Nervous System Neoplasms / Q000150:complications / Q000401:mortality / Q000556:secondary / Q000628:therapy*; D002648:Child; D002675:Child, Preschool; D018572:Disease-Free Survival; D005260:Female; D006086:Graft vs Host Disease / Q000209:etiology / Q000401:mortality; D018380:Hematopoietic Stem Cell Transplantation; D006801:Humans; D007037:Hypothyroidism / Q000209:etiology / Q000401:mortality; D008607:Intellectual Disability / Q000209:etiology / Q000401:mortality; D016399:Lymphoma, T-Cell / Q000150:complications / Q000401:mortality / Q000628:therapy; D008297:Male; D054198:Precursor Cell Lymphoblastic Leukemia-Lymphoma / Q000150:complications / Q000401:mortality / Q000628:therapy*; D011788:Quality of Life; D012008:Recurrence; D014184:Transplantation, Homologous